(Reuters) – U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals to support its growth.
Abbvie’s deal to buy Cerevel is its second large deal in the past week, after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash.
(Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru; Editing by Krishna Chandra Eluri)
